Nordic Meeting 2024 in Stockholm

This year, the Nordic meeting took place in Stockholm, Sweden on 15.03-17.03.2024, and Annabel Kattai and Ines Vaide from the Estonian Hemophilia Society participated there.
The guiding motto of the meeting was: "Equal and safe health and well-being for all"

During the three days, the following topics were covered:
On the first day - 60 years of experience of the Swedish Hemophilia Society. Getting to know the participants through organized individual conversations "speed dating", the associations were divided behind different tables and could thus get to know each other better and listen to different stories.

On the second day, the first part of the main day introduced the activities of the Nordic Pharmaceutical Forum established in 2015, the problems with the entry and availability of new drugs on the market in different countries, and the future goals.
The second half of the day was opened by Nicklas, who spoke about his gene therapy journey, being the first patient with hemophilia B from Sweden to undertake this journey.
Continued with the discussion of future joint work between EHC and the Nordic countries - the topics were funding opportunities from EHC and how the work of EHC is different associations satisfied and what not.
We ended the day by presenting the activities of the Nordic and Baltic countries, which we did in 2023 and what we expect from 2024.

The Sunday lectures were opened by Stockholm's laboratory doctor: dr. Antovic with the topic - the risk of cardiovascular diseases in hemophilia patients due to aging.
The day ended with a "round table" of pharmaceutical companies where it was heard:
-Who has VIII. factor concentrates and which pharmaceutical companies produce VWD factors.
-Which pharmaceutical companies are engaged in the production of new factors and who think that in the future there should be no more plasters in medicine boxes.
-We also found out which pharmaceutical companies operate in the Baltic and Nordic countries and why it is important to them that people with bleeding disorders receive adequate treatment and what happens when plasma-based factor can no longer be produced, and what is their perspective on this.

We ended the conference with new knowledge and acquaintances!

Skip to content